aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

aTyr Pharma (LIFE) reports robust Q4 earnings, advances lead candidate

aTyr Pharma (LIFE) is well-positioned with a strong financial standing, a focus on innovative drug development for inflammatory diseases, and ongoing clinical trials for lead candidate efzofitimod targeting ILD and pulmonary sarcoidosis. While facing challenges in addressing analyst inquiries, the company has opportunities to advance its pipeline and leverage its financial resources for future growth.

aTyr Pharma progresses efzofitimod for ILD treatment, eyes transformative growth

aTyr Pharma's strong performance in advancing efzofitimod, solid financial position, and focus on innovation position them well for future growth and success
While facing challenges in pivotal studies and program management, the company's opportunities in pipeline expansion and disruptive drug discovery set a positive trajectory

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patients Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patients

aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

Management to host conference call and webcast on August 15th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on August 15th at 5:00 pm EDT / 2:00 pm PDT

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

Evofem Biosciences Inc

22nd Century Group

Analysts say these are penny stocks to buy, do you agree? The post Best Penny Stocks to Buy Now According To 3 Top Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Now According To 3 Top Analysts

Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair.

aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment

Conference hosted by The Ohio State University's Center for RNA Biology to showcase latest advancements in tRNA biology Conference hosted by The Ohio State University's Center for RNA Biology to showcase latest advancements in tRNA biology

aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the 2022 Jefferies Healthcare Conference, which is scheduled to take place June 8 – 10, 2022, in New York, NY.

aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference

aTyr Pharma, Inc. (NASDAQ:LIFE ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Dr. Sanjay S. Shukla – President and Chief Executive Officer Jill Broadfoot – Chief Financial Officer Ashlee Dunston – Director, Investor Relations and Corporate Communications Conference Call Participants Hartaj Singh – Oppenheimer & Company Zegbeh Jallah – ROTH Capital Partners Yale Jen – Laidlaw & Company Operator Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma First Quarter 2022 Conference Call.

aTyr Pharma, Inc. (LIFE) CEO Dr. Sanjay S. Shukla on Q1 2022 Results - Earnings Call Transcript

Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May.

aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update

Management to host conference call and webcast on May 9th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on May 9th at 5:00 pm EDT / 2:00 pm PDT

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results

The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.

aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod

Second U.S. orphan drug designation for efzofitimod clinical program Second U.S. orphan drug designation for efzofitimod clinical program

aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis

Findings suggest that ATYR2810 reduces metastasis and enhances chemosensitivity by downregulating key genes linked to these processes. Findings suggest that ATYR2810 reduces metastasis and enhances chemosensitivity by downregulating key genes linked to these processes.

aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting

The consensus price target hints at a 235.8% upside potential for Atyr Pharma (LIFE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Atyr Pharma (LIFE) Have the Potential to Rally 236% as Wall Street Analysts Expect?

Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints.

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

The consensus price target hints at a 265.6% upside potential for Atyr Pharma (LIFE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Atyr Pharma (LIFE) Climb 266% to Reach the Level Wall Street Analysts Expect?

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2021 Results - Earnings Call Transcript

FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarter of 2022.

aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update

Regulatory path forward supports company's intention to initiate a planned registrational study in the third quarter of 2022. Regulatory path forward supports company's intention to initiate a planned registrational study in the third quarter of 2022.

aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8 – 13, 2022, in New Orleans, LA, and virtually.

aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2021 Financial Results

Panel to take place on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST Panel to take place on Monday, February 28, 2022, at 2:55pm EST / 11:55am PST

aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day®

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference, which is being held February 14 – 17, 2022, at the Marriott Marquis in New York, NY.

aTyr Pharma to Present at BIO CEO & Investor Conference

Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022 Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022

aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 10 – 13, 2022.

aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

aTyr's lead candidate ATYR1923 recently came out with strong data in a proof of concept trial. Lead indication has a large market in the US.

News for aTyr Pharma Stock (LIFE)